GlassScriptPhysician profile
Lauren E Skyles
NPI 1811406242
$1,808.59
in general payments reported to CMS, 2019-2025
28 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $189 · 2023: $26.58 · 2024: $65.99 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $202.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.11 | 2021-2024 | |
| Lilly USA, LLC | $157.46 | 2021-2025 | Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $145.48 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $141.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.56 | 2021 | |
| Novo Nordisk INC | $118.09 | 2021 | |
| Pfizer INC. | $106.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.55 | 2021 | |
| Amarin Pharma, INC. | $90.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.21 | 2021 | |
| Acella Pharmaceuticals, LLC | $63.60 | 2022-2025 | NP Thyroid 60 |
| Optinose US, INC. | $50.57 | 2021 | |
| Glaxosmithkline, LLC. | $48.76 | 2021 | |
| Daiichi Sankyo INC. | $46.20 | 2021 | |
| Merck Sharp & Dohme LLC | $44.10 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.09 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.43 | 2021 | |
| Paratek Pharmaceuticals, INC. | $25.15 | 2021 | |
| Dexcom, INC. | $24.69 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $19.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.47 | 2021 | |
| Gilead Sciences, INC. | $15.59 | 2021 | |
| Astellas Pharma US INC | $15.41 | 2021 | |
| Alfasigma USA, INC. | $13.62 | 2022 | |
| Amgen INC. | $13.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.67 | 2022 | |
| Esperion Therapeutics, INC. | $12.48 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Skyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.